Here's a list of some potential catalysts, other than the top two:
●End of enrollment for the ulcerative colitis trial
●Initiation of the GvHD phase II/III trial
●Initiation of the acute myocardial infarction phase II trial
●Realization of a partnership for the obesity drug
●Realization of a partnership for ischemic stroke
●Future grants or awards
●Potential milestone payments from RTI or Pfizer
●Legislation for Regenerative Medicine in Japan, may bring fast development path news.
Now the real movers:
The UC trial due at the end of the first quarter in 2014... easy pop to $7 on continuation to phase III * The phase III trial may be designed for crohn's disease.
The IS trial due mid 2014... easy pop to $10 and that's being conservative with new laws in Japan. Phase III may not even be needed to market it in Japan.
A holder of this stock asked that Athersys have an offering... Athersys did without a severe undercut of the share price. Couple this with the ability to draw down on the Aspire deal if needed and we have a bright future for Athersys ahead. Stroke is a slam dunk - follow the trials and Youtube video. The guy was healing faster than normal. .